Comparing Rockwell Medical (NASDAQ:RMTI) and Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH) and Rockwell Medical (NASDAQ:RMTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Volatility & Risk

Delcath Systems has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Delcath Systems and Rockwell Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0	2	2	0	2.50
Rockwell Medical	2	0	1	0	1.67

Delcath Systems presently has a consensus price target of $26.67, suggesting a potential upside of 79.85%. Rockwell Medical has a consensus price target of $20.00, suggesting a potential upside of 161.44%. Given Rockwell Medical’s higher possible upside, analysts clearly believe Rockwell Medical is more favorable than Delcath Systems.

Profitability

This table compares Delcath Systems and Rockwell Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Rockwell Medical	-7.33%	-14.03%	-8.90%

Earnings and Valuation

This table compares Delcath Systems and Rockwell Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$95.42 million	5.39	$2.70 million	$0.01	1,482.70
Rockwell Medical	$69.39 million	0.44	-$5.31 million	($1.34)	-5.71

Delcath Systems has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 4.6% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Delcath Systems beats Rockwell Medical on 12 of the 14 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.